X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Pharma Giants Spearhead Eco-Friendly Healthcare Transition

Content Team by Content Team
29th August 2023
in Facilities & Operation, Featured, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Pharmaceutical companies have collaborated with the WHO through the Sustainable Markets Initiative to implement new supplier requirements, aiming to hasten the healthcare sector’s shift to net-zero emissions. The CEOs of AstraZeneca, GSK, Novo Nordisk, Merck, Roche, Sanofi, and Samsung Biologics jointly penned a letter detailing these requirements, with supply chain emissions accounting for over half of the global healthcare sector’s carbon footprint.

The letter introduces “minimum” targets for suppliers, mandating the assessment and disclosure of emissions across all three Scopes by 2025. Suppliers are also expected to commit to near-term goals aligned with the 1.5-degree Celsius pathway through the Science Based Targets initiative (SBTi). By 2025, they must establish targets for waste and energy reduction in manufacturing processes, as well as commit to transitioning to at least 80% renewable energy by 2030.

Furthermore, suppliers are charged with exploring methods to decrease heat-related emissions by 2030, setting standards for their own suppliers, and adopting water efficiency practices. Transport suppliers have until 2025 to make SBTi-aligned commitments and incorporate green transportation solutions by 2030.

The joint letter emphasizes the necessity of greener, more efficient, and circular healthcare supply chains. The companies assert that collaboration across the value chain is essential for decarbonization and the shift away from fossil fuels. These commitments build upon core actions initiated at COP27 and extend the companies’ impact beyond their individual organizations.

These seven companies are partners in the WHO-led Alliance for Transformative Action on Climate and Health (ATACH), which facilitates knowledge sharing among healthcare organizations in over 70 countries.

The focus on suppliers follows a year of internal efforts by the companies within the framework of the Sustainable Markets Initiative. In November 2022, the companies agreed to a new operational roadmap. This roadmap includes plans to explore renewable power purchase agreements in China and India in 2023 and to evaluate low or zero-carbon heat solutions by 2025, aiming for 100% renewable energy use. Additionally, the roadmap outlines a commitment to transitioning all vehicle fleets to 100% zero-emission vehicles within the decade.

Regarding Scope 3 emissions, the SBTi recently issued guidance for larger companies to engage with their supply chains and encourage suppliers to establish science-based targets. Supply chains often harbor significant negative impacts, generating more emissions and other environmental issues than a company’s operations alone. To address these challenges, discussions and insights were shared during edie’s Scope 3 Emissions Workshops, resulting in a comprehensive report that details the significance of Scope 3 emissions and offers guidance for businesses aiming to reduce them.

Previous Post

Overcoming Emission Challenges For Pharma Sustainability

Next Post

Temperature Management For Pharmaceutical Logistics Success

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Temperature Management For Pharmaceutical Logistics Success

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In